SCHEMBL2346381

SCHEMBL2346381

COc1cc(OC(=O)C(C)C)ccc1-c1ccc2c(c1C(O)C(=O)c1ccc(C)cc1)C(C)=CC(C)(C)N2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.45
LMNA P02545 7/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
TDP1 Q9NUW8 2/20 0.45
HTT P42858 6/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
NR3C1 P04150 9/20 0.39
NR3C2 P08235 1/20 0.39
AR P10275 1/20 0.39
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 2/20 0.39
NPSR1 Q6W5P4 5/20 0.38
TP53 P04637 3/20 0.38
HSD17B10 Q99714 2/20 0.38
PGR P06401 4/20 0.38
HPGD P15428 2/20 0.38
G6PD P11413 1/20 0.36
GFER P55789 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1831662 0.85 NR3C1 (0.40) MAPTLMNASMN1; SMN2L3MBTL1TDP1
SCHEMBL1780613 0.82 MAPT (0.44) MAPTLMNASMN1; SMN2L3MBTL1TDP1
SCHEMBL462616 0.79 PGR (0.49) NR3C1NR3C2ARPGR
SCHEMBL4418729 0.74 MAPT (0.39) MAPTLMNASMN1; SMN2L3MBTL1TDP1
SCHEMBL1315761 0.74 MAPT (0.46) MAPTLMNASMN1; SMN2L3MBTL1TDP1
SCHEMBL4423368 0.73 MAPT (0.39) MAPTLMNASMN1; SMN2L3MBTL1TDP1
SCHEMBL1783306 0.73 MAPT (0.41) MAPTLMNASMN1; SMN2L3MBTL1TDP1
SCHEMBL1780349 0.72 MAPT (0.47) MAPTLMNASMN1; SMN2L3MBTL1TDP1
SCHEMBL1313675 0.72 IL6 (0.54) MAPTLMNASMN1; SMN2L3MBTL1TDP1
SCHEMBL2352338 0.72 NR3C1 (0.49) MAPTLMNAL3MBTL1TDP1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008497-B2 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-08-30 US disclosed
US-20090298826-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298826-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS NR3C1, NR3C2, NR5A1 MAPT 4861/4885LMNA 4460/4885SMN1; SMN2 4700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.